MNE P201
Alternative Names: MNE-P201; Personalised mRNA vaccine - myNEO Therapeutics; PRIMYO - myNeo TherapeuticsLatest Information Update: 12 Sep 2026
At a glance
- Originator myNEO
- Developer myNEO Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Sep 2026 Preclinical trials in Solid tumours in Belgium (Parenteral), prior to September2026 (myNEO Therapeutics pipeline, September 2026)
- 23 Jan 2025 Early research in Solid tumours in Belgium (Parenteral) before January 2025 (myNEO pipeline, January 2025)
- 04 Sep 2024 myNEO has a patent protection for 'Method, system and computer program product for determining presentation likelihoods of neoantigens' in Europe